<DOC>
	<DOCNO>NCT01405924</DOCNO>
	<brief_summary>This study ass efficacy single dose intravenous ( IV ) fosaprepitant ( MK-0517 , EMEND® IV ) salvage therapy add 5-hydroxytryptamine receptor 3 antagonist ( 5-HT3 RA ) dexamethasone prevention chemotherapy-induced vomiting ( CIV ) participant experience CIV first cycle moderately emetic chemotherapy ( MEC ) . The primary hypothesis vomit retch least 20 % participant second cycle MEC participants previously experience vomit first cycle MEC .</brief_summary>
	<brief_title>Fosaprepitant ( MK-0517 , EMEND® IV ) In Salvage Treatment Chemotherapy-Induced Vomiting ( MK-0517-030 )</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosed either breast gynecological cancer Receiving either AClike CT MEC Experienced least 1 episode vomit retch first 5 day follow Cycle 1 chemotherapy think due chemotherapy . Received standard chemotherapyinduced nausea vomiting ( CINV ) prophylaxis contain aprepitant fosaprepitant No change chemotherapy Cycle 2 No change Cycle 1 antiemetic regimen Cycle 2 Eastern Cooperative Oncology Group ( ECOG ) status 01 Requires increase systemic corticosteroid therapy Used benzodiazepine opiates 48 hour prior Cycle 2 chemotherapy Received receive radiation therapy abdomen pelvis week prior Visit 1 Days 16 follow chemotherapy Vomited 24 hour prior Treatment Day 1 Pregnant breastfeed Participating study aprepitant fosaprepitant take investigational drug last 4 week Symptomatic central nervous system metastasis History malignancy last 2 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>